Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication?

Nishant D. Patel, Jason A. Williams, Lois U. Nwakanma, Michele M. Waldron, David A. Bluemke, John V. Conte

Research output: Contribution to journalArticle

Abstract

Background: Surgical ventricular restoration (SVR) is an established therapy for congestive heart failure due to ischemic cardiomyopathy. Pulmonary hypertension (PHTN) has been considered a contraindication for SVR owing to a presumed increase in operative risk. However, outcomes in these patients and the impact of SVR on PHTN have not been specifically evaluated. Methods: We retrospectively reviewed SVR patients between January 2002 and June 2005. Patients were classified as PHTN (mean pulmonary artery pressure ≥ 25 mm Hg) and no PHTN (mPAP <25 mm Hg) based on preoperative cardiac catheterization. Cardiac function was assessed using magnetic resonance imaging and echocardiography. Follow-up was 100%. Results: Sixty-nine patients underwent SVR for congestive heart failure. Thirty-six percent (25 of 69) had preoperative PHTN. Preoperatively, PHTN patients had significantly lower ejection fraction (21.1% versus 30.0%; p = 0.005) and larger left ventricular end-systolic volume index (119.0 versus 88.7 mL/m2; p = 0.04) than patients without PHTN. All PHTN patients and 95.5% (42 of 44) of the no PHTN group were New York Heart Association (NYHA) class III/IV preoperatively. There was 1 operative death in the PHTN group. Surgical ventricular restoration significantly improved cardiac function and pulmonary pressures for PHTN patients. Both groups had similar cardiac function postoperatively. Seventy-two percent (18 of 25) of PHTN patients and 69.0% (29 of 42) of patients without PHTN improved to NYHA class I/II at follow-up. Kaplan-Meier survival of PHTN patients was 68.1% at 3 years, which was lower than patients without PHTN (81.4%; p = 0.44), but not statistically significant. Kaplan-Meier 3-year survival for all SVR patients was 76.6%. Conclusions: Surgical ventricular restoration is a good treatment option in patients with advanced congestive heart failure and PHTN. Our early results are promising and should prompt further studies to confirm these findings.

Original languageEnglish (US)
Pages (from-to)879-888
Number of pages10
JournalAnnals of Thoracic Surgery
Volume82
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Pulmonary Hypertension
Heart Failure
Pressure
Survival
Cardiac Catheterization
Cardiomyopathies
Stroke Volume
Pulmonary Artery
Echocardiography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Surgical Ventricular Restoration for Advanced Congestive Heart Failure : Should Pulmonary Hypertension Be a Contraindication? / Patel, Nishant D.; Williams, Jason A.; Nwakanma, Lois U.; Waldron, Michele M.; Bluemke, David A.; Conte, John V.

In: Annals of Thoracic Surgery, Vol. 82, No. 3, 09.2006, p. 879-888.

Research output: Contribution to journalArticle

Patel, Nishant D. ; Williams, Jason A. ; Nwakanma, Lois U. ; Waldron, Michele M. ; Bluemke, David A. ; Conte, John V. / Surgical Ventricular Restoration for Advanced Congestive Heart Failure : Should Pulmonary Hypertension Be a Contraindication?. In: Annals of Thoracic Surgery. 2006 ; Vol. 82, No. 3. pp. 879-888.
@article{79e35e136aef4c1893bf67d84f0c0e4e,
title = "Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication?",
abstract = "Background: Surgical ventricular restoration (SVR) is an established therapy for congestive heart failure due to ischemic cardiomyopathy. Pulmonary hypertension (PHTN) has been considered a contraindication for SVR owing to a presumed increase in operative risk. However, outcomes in these patients and the impact of SVR on PHTN have not been specifically evaluated. Methods: We retrospectively reviewed SVR patients between January 2002 and June 2005. Patients were classified as PHTN (mean pulmonary artery pressure ≥ 25 mm Hg) and no PHTN (mPAP <25 mm Hg) based on preoperative cardiac catheterization. Cardiac function was assessed using magnetic resonance imaging and echocardiography. Follow-up was 100{\%}. Results: Sixty-nine patients underwent SVR for congestive heart failure. Thirty-six percent (25 of 69) had preoperative PHTN. Preoperatively, PHTN patients had significantly lower ejection fraction (21.1{\%} versus 30.0{\%}; p = 0.005) and larger left ventricular end-systolic volume index (119.0 versus 88.7 mL/m2; p = 0.04) than patients without PHTN. All PHTN patients and 95.5{\%} (42 of 44) of the no PHTN group were New York Heart Association (NYHA) class III/IV preoperatively. There was 1 operative death in the PHTN group. Surgical ventricular restoration significantly improved cardiac function and pulmonary pressures for PHTN patients. Both groups had similar cardiac function postoperatively. Seventy-two percent (18 of 25) of PHTN patients and 69.0{\%} (29 of 42) of patients without PHTN improved to NYHA class I/II at follow-up. Kaplan-Meier survival of PHTN patients was 68.1{\%} at 3 years, which was lower than patients without PHTN (81.4{\%}; p = 0.44), but not statistically significant. Kaplan-Meier 3-year survival for all SVR patients was 76.6{\%}. Conclusions: Surgical ventricular restoration is a good treatment option in patients with advanced congestive heart failure and PHTN. Our early results are promising and should prompt further studies to confirm these findings.",
author = "Patel, {Nishant D.} and Williams, {Jason A.} and Nwakanma, {Lois U.} and Waldron, {Michele M.} and Bluemke, {David A.} and Conte, {John V.}",
year = "2006",
month = "9",
doi = "10.1016/j.athoracsur.2006.04.016",
language = "English (US)",
volume = "82",
pages = "879--888",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Surgical Ventricular Restoration for Advanced Congestive Heart Failure

T2 - Should Pulmonary Hypertension Be a Contraindication?

AU - Patel, Nishant D.

AU - Williams, Jason A.

AU - Nwakanma, Lois U.

AU - Waldron, Michele M.

AU - Bluemke, David A.

AU - Conte, John V.

PY - 2006/9

Y1 - 2006/9

N2 - Background: Surgical ventricular restoration (SVR) is an established therapy for congestive heart failure due to ischemic cardiomyopathy. Pulmonary hypertension (PHTN) has been considered a contraindication for SVR owing to a presumed increase in operative risk. However, outcomes in these patients and the impact of SVR on PHTN have not been specifically evaluated. Methods: We retrospectively reviewed SVR patients between January 2002 and June 2005. Patients were classified as PHTN (mean pulmonary artery pressure ≥ 25 mm Hg) and no PHTN (mPAP <25 mm Hg) based on preoperative cardiac catheterization. Cardiac function was assessed using magnetic resonance imaging and echocardiography. Follow-up was 100%. Results: Sixty-nine patients underwent SVR for congestive heart failure. Thirty-six percent (25 of 69) had preoperative PHTN. Preoperatively, PHTN patients had significantly lower ejection fraction (21.1% versus 30.0%; p = 0.005) and larger left ventricular end-systolic volume index (119.0 versus 88.7 mL/m2; p = 0.04) than patients without PHTN. All PHTN patients and 95.5% (42 of 44) of the no PHTN group were New York Heart Association (NYHA) class III/IV preoperatively. There was 1 operative death in the PHTN group. Surgical ventricular restoration significantly improved cardiac function and pulmonary pressures for PHTN patients. Both groups had similar cardiac function postoperatively. Seventy-two percent (18 of 25) of PHTN patients and 69.0% (29 of 42) of patients without PHTN improved to NYHA class I/II at follow-up. Kaplan-Meier survival of PHTN patients was 68.1% at 3 years, which was lower than patients without PHTN (81.4%; p = 0.44), but not statistically significant. Kaplan-Meier 3-year survival for all SVR patients was 76.6%. Conclusions: Surgical ventricular restoration is a good treatment option in patients with advanced congestive heart failure and PHTN. Our early results are promising and should prompt further studies to confirm these findings.

AB - Background: Surgical ventricular restoration (SVR) is an established therapy for congestive heart failure due to ischemic cardiomyopathy. Pulmonary hypertension (PHTN) has been considered a contraindication for SVR owing to a presumed increase in operative risk. However, outcomes in these patients and the impact of SVR on PHTN have not been specifically evaluated. Methods: We retrospectively reviewed SVR patients between January 2002 and June 2005. Patients were classified as PHTN (mean pulmonary artery pressure ≥ 25 mm Hg) and no PHTN (mPAP <25 mm Hg) based on preoperative cardiac catheterization. Cardiac function was assessed using magnetic resonance imaging and echocardiography. Follow-up was 100%. Results: Sixty-nine patients underwent SVR for congestive heart failure. Thirty-six percent (25 of 69) had preoperative PHTN. Preoperatively, PHTN patients had significantly lower ejection fraction (21.1% versus 30.0%; p = 0.005) and larger left ventricular end-systolic volume index (119.0 versus 88.7 mL/m2; p = 0.04) than patients without PHTN. All PHTN patients and 95.5% (42 of 44) of the no PHTN group were New York Heart Association (NYHA) class III/IV preoperatively. There was 1 operative death in the PHTN group. Surgical ventricular restoration significantly improved cardiac function and pulmonary pressures for PHTN patients. Both groups had similar cardiac function postoperatively. Seventy-two percent (18 of 25) of PHTN patients and 69.0% (29 of 42) of patients without PHTN improved to NYHA class I/II at follow-up. Kaplan-Meier survival of PHTN patients was 68.1% at 3 years, which was lower than patients without PHTN (81.4%; p = 0.44), but not statistically significant. Kaplan-Meier 3-year survival for all SVR patients was 76.6%. Conclusions: Surgical ventricular restoration is a good treatment option in patients with advanced congestive heart failure and PHTN. Our early results are promising and should prompt further studies to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=33747367923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747367923&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2006.04.016

DO - 10.1016/j.athoracsur.2006.04.016

M3 - Article

C2 - 16928501

AN - SCOPUS:33747367923

VL - 82

SP - 879

EP - 888

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -